Pinned post
Massive thanks to everyone who came together to make NextMed.Health 2025 a magical gathering of innovators and changemakers at the interface of technology healthcare and the human spirit.
#NextMedHealth
#NextMedHealth
NextMed Health
Verified account This account is verified. Learn more@NextMedHealth
NextMed.Health is a cross-disciplinary program & community from across #healthtech & biomedicine reimagining the future of health & biomedicine.
3.1K Following 26K Followers 11K Posts
Latest posts 5
NOW: Leaky heart valves, fixed without reopening the chest. FDA just approved Abbott's Amplatzer Paraclose, the first US catheter device built to plug leaks around surgically replaced heart valves. abbott.mediaroom.com/press-releases…
NEAR: Brain stimulation that gives feedback in minutes, not months. Mayo Clinic found that deep brain stimulation for hard-to-treat epilepsy changes brain connectivity within 18 minutes. That could become a fast signal for tuning each patient's settings. newsnetwork.mayoclinic.org/discussion/may…
NEXT: Genetic "kill switches" that sculpt mini-organs. University of Pittsburgh scientists built self-destruct circuits that remove faulty cells as lab-grown tissue develops, which yielded more mature liver organoids. It's a step toward truer human tissue models and regenerative medicine. path.pitt.edu/news/dr-mo-ebr…
@NextMedHealth • NextMed.Health
#FutureOfHealth
NEAR: Brain stimulation that gives feedback in minutes, not months. Mayo Clinic found that deep brain stimulation for hard-to-treat epilepsy changes brain connectivity within 18 minutes. That could become a fast signal for tuning each patient's settings. newsnetwork.mayoclinic.org/discussion/may…
NEXT: Genetic "kill switches" that sculpt mini-organs. University of Pittsburgh scientists built self-destruct circuits that remove faulty cells as lab-grown tissue develops, which yielded more mature liver organoids. It's a step toward truer human tissue models and regenerative medicine. path.pitt.edu/news/dr-mo-ebr…
@NextMedHealth • NextMed.Health
#FutureOfHealth
NOW / NEAR / NEXT — Oct 3
NOW: First FDA-approved treatment for MCT8 deficiency (Allan-Herndon-Dudley). Emcitate (tiratricol) lowers excess thyroid hormone when the brain’s hormone transporter is broken.
fda.gov/news-events/pr…
NEAR: Aging-cell “senolytic” drugs ease fatty-liver scarring. In fibrotic MASH, dasatinib + quercetin improved fibrosis in 47% vs 7% on placebo (phase 2, Nature Metabolism).
nature.com/articles/s4225…
NEXT: Gene editing reawakens embryonic ζ-globin — a path to treat severe α-thalassemia without lifelong transfusion (Nature Genetics).
nature.com/articles/s4158…
@NextMedHealth | NextMed.Health
NOW: First FDA-approved treatment for MCT8 deficiency (Allan-Herndon-Dudley). Emcitate (tiratricol) lowers excess thyroid hormone when the brain’s hormone transporter is broken.
fda.gov/news-events/pr…
NEAR: Aging-cell “senolytic” drugs ease fatty-liver scarring. In fibrotic MASH, dasatinib + quercetin improved fibrosis in 47% vs 7% on placebo (phase 2, Nature Metabolism).
nature.com/articles/s4225…
NEXT: Gene editing reawakens embryonic ζ-globin — a path to treat severe α-thalassemia without lifelong transfusion (Nature Genetics).
nature.com/articles/s4158…
@NextMedHealth | NextMed.Health
NOW / NEAR / NEXT — the future of health & biomedicine, today.
NOW: FDA clears Onswik — a once-weekly basal insulin for adults with type 2 diabetes. Daily-level A1C control, far fewer injections.
fda.gov/drugs/news-eve…
NEAR: An AI model reading pathology + clinical data beat the standard 21-gene test at predicting early and late breast cancer recurrence. Next up: trials that could guide treatment choices.
ascopost.com/news/september…
NEXT: AI designs solid-state mRNA vaccines that kept full potency after 2+ months at body temperature — a path to fridge-free shots and microneedle patches worldwide.
nature.com/articles/s4158…
#HealthTech #FutureOfHealth
NOW: FDA clears Onswik — a once-weekly basal insulin for adults with type 2 diabetes. Daily-level A1C control, far fewer injections.
fda.gov/drugs/news-eve…
NEAR: An AI model reading pathology + clinical data beat the standard 21-gene test at predicting early and late breast cancer recurrence. Next up: trials that could guide treatment choices.
ascopost.com/news/september…
NEXT: AI designs solid-state mRNA vaccines that kept full potency after 2+ months at body temperature — a path to fridge-free shots and microneedle patches worldwide.
nature.com/articles/s4158…
#HealthTech #FutureOfHealth
NOW · NEAR · NEXT
NOW: First drug for Alexander disease. FDA approved Zanvastro (zilganersen) — an RNA medicine that dials down toxic GFAP.
fda.gov/news-events/pr…
NEAR: Lonvo-z, Intellia’s in vivo CRISPR for HAE — rolling BLA underway; potential U.S. launch H1 2027 if approved. One shot vs lifelong prophylaxis.
ir.intelliatx.com/news-releases/…
NEXT: Cellular rejuvenation enters humans. Life Bio dosed the first patient with ER-100 (OSK epigenetic reprogramming) for optic neuropathies.
lifebiosciences.com/life-bioscienc…
NOW: First drug for Alexander disease. FDA approved Zanvastro (zilganersen) — an RNA medicine that dials down toxic GFAP.
fda.gov/news-events/pr…
NEAR: Lonvo-z, Intellia’s in vivo CRISPR for HAE — rolling BLA underway; potential U.S. launch H1 2027 if approved. One shot vs lifelong prophylaxis.
ir.intelliatx.com/news-releases/…
NEXT: Cellular rejuvenation enters humans. Life Bio dosed the first patient with ER-100 (OSK epigenetic reprogramming) for optic neuropathies.
lifebiosciences.com/life-bioscienc…
